Vanguard Group Inc. Sells 100,781 Shares of Illumina, Inc. (NASDAQ:ILMN)

Vanguard Group Inc. reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by 0.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,813,419 shares of the life sciences company’s stock after selling 100,781 shares during the period. Vanguard Group Inc. owned 9.97% of Illumina worth $2,113,147,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Golden State Wealth Management LLC acquired a new position in shares of Illumina during the 4th quarter worth about $32,000. Versant Capital Management Inc grew its holdings in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Illumina during the fourth quarter valued at approximately $45,000. Assetmark Inc. raised its holdings in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after purchasing an additional 296 shares during the period. Finally, Lee Danner & Bass Inc. acquired a new stake in Illumina in the fourth quarter worth $48,000. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Citigroup lowered their price objective on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Royal Bank of Canada lowered their price target on Illumina from $247.00 to $128.00 and set an “outperform” rating for the company in a report on Wednesday, March 12th. Hsbc Global Res cut Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. Robert W. Baird lowered their target price on Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, March 5th. Finally, HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Trading Down 5.4 %

Shares of Illumina stock opened at $82.83 on Thursday. The stock has a market cap of $13.12 billion, a P/E ratio of -10.79, a P/E/G ratio of 1.60 and a beta of 1.17. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12-month low of $80.18 and a 12-month high of $156.66. The business’s 50 day moving average is $105.03 and its 200-day moving average is $127.40.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.